Slide 1: Immunic
{ |mmunic
Slide 2: Cautionary Note Regarding Forward-Looking Statements
Cautionary Note Regarding Forward-Looking Statements 25 for purposes ofthesafeharbor within the meaning ofS irities Act ice statementsregardingm anagem ent’ sintentions, plans, beliefs, nsor n them. 1 kingstatement c: dl, and actual resultsmay differ materially from ing statement, whether asa result
Slide 3: Agenda
Agenda Fourth Quarter and Year End 2022 Financial Results and Corporate Update 02 | Fourth Quarter 2022 and Subsequent Highlights Q&A Session 02 | Financial and Operating Results Summary and Highlights Anticipated Clinical Milestones 3 | ©immunic, inc, | Feb/23/2023 © |mmunic
Slide 4: Fourth Quarter 2022 and Subsequent Highlights
Slide 5: October: Closed USD Million Private Placement, Extending Cash Runway Into Q4/2024
October: Closed USD 60 Million Private Placement, Extending Cash Runway Into Q4/2024 Summary Gross / Net Proceeds Participating Investors Closing Date Lead Placement Agent / ment Agent 5 | ©immunic, ine. | Feb; Private investment in public equity (“PIPE”) financing Aggregate of & 552 shares of commo
Slide 6: October: Reported Group-Level Interim Data of Phase 1b Trial of IMU-935 in Psoriasis
6 | ©tmmunie, inc. | Feb/23/2028 October: Reported Group-Level Interim Data of Phase 1b Clinical Trial of IMU-935 in Moderate-to-Severe Psoriasis Identifying Therapeutic Activity of IMU-935 in Moderate-to-Severe Psoriasis Patients = 28-day double-blind, placebo-controlled dose escalation trial to ev
Slide 7: November: Hosted Virtual Multiple Sclerosis R&D Webcast
November: Hosted Virtual Multiple Sclerosis R&D Webcast Is Everything Different? Latest Exciting Scientific Findings and Their Effect on The Multiple Sclerosis Treatment AGENDA Is Everything Different? Latest Exciting Scientific Findings and Their Effect on the MS Treatment Landscape FEATURED KEY OP
Slide 8: November: Reported New Data From Phase 2 EMPhASIS Trial in RRMS
saan | aa November: Reported New Data From Phase 2 EMPhASIS Trial in RRMS Supporting Vidofludimus Calcium’s Neuroprotective Potential Data showed encouraging signals for vidofludimus calcium for preventing or delaying confirmed disability worsening Long-term open-label treatment associated with a lo
Slide 9: February: Hosted Virtual Celiac Disease R&D Webcast
February: Hosted Virtual Celiac Disease R&D Webcast Treatment of Celiac Disease Hin Current Pathways for Drug Development & Persistent. Activity Despite Gluten-Free Diet as the Unmet Medical Current Pathways for Drug Development & Persistent Disease Activity Despite Gluten-Free Diet as the Unmet Med
Slide 10: February: Announced Presentation of Data From Phase 2 EMPhASIS Trial at ACTRIMS Forum 2023
February: Announced Presentation of Data From Phase 2 EMPhASIS Trial at ACTRIMS Forum 2023 "eater andl Roeeroh fullplel and oper label extension penods ofthe phase 2 study (EMPnASIS) in rtspsingemting mutiple sclerosis : , . Treatment and Research in Multiple Sclerosis The eighth annual Americas Com
Slide 11: Financial and Operating Results
Slide 12: Condensed Consolidated Statements of Operations
Condensed Consolidated Statements of Operations (In thousands, except share and per share amounts, unaudited) Years Ended December 31, 2022 2021 Operating expenses: Research and development $71,255 $61,115 General and administrative 15,263 13,300 Goodwill impairment 32,970 =| ASC Royalty Settlement
Slide 13: Anticipated Clinical Milestones
Slide 14: Vidofludimus Calcium in Multiple Sclerosis
Vidofludimus Calcium in Multiple Sclerosis Straightforward Approval Strategy Phase 2 CALLIPER Trial in PMS?! = Phase 2 trial in PMS patients = Goal: Demonstrate vidofludimus calcium’s potential for neuroprotective activity in a non- relapse setting * Dosage: 30 mg vidofludimus calcium QD = Dosage: 4
Slide 15: IMU-935 Phase 1 Clinical Trial in Psoriasis
IMU-935 Phase 1 Clinical Trial in Psoriasis , Immunic expects to provide further updates and guidance on potential next steps for the phase 1 clinical trial of IMU-935 in moderate-to-severe psoriasis towards the end of Q1/2023. & |mmunic
Slide 16: IMU-856 Phase 1 Clinical Trial in Celiac Disease
IMU-856 Phase 1 Clinical Trial in Celiac Disease Initial data from the ongoing Part C of the phase 1 clinical trial of IMU-856 in celiac disease patients is expected to be available in mid-2023. & |mmunic 46 | ©immunic, inc, | Feb/23/202
Slide 17: Q&A Session
Slide 18: Summary and Highlights
Slide 19: Advanced Clinical Pipeline
Advanced Clinical Pipeline Three Differentiated Programs in Various Phases of Clinical Development Program _ | Target Preclinical Phase 1 Phase 2 Phase 3 Key Milestones = Initial phase 1b celiac disease data of Relapsing Multiple Sclerosis (RMS) — ENSURE Trials IMU-856 expected in mid-2023 Vidofludi
Slide 20: Thank You!
Thank You! Head of IR & Communications Phone: +49-89-2080477-09 Email: ir@imux.com Web: www.imux.com 20 | ©immunie, ine, | Feb/23/2023 Immunic, Ine. 1200 Avenue of the Americas New York City, NY 10036 USA Immunic AG Lochhamer Schlag 21 82.166 Grifelfing (Munich) Germany Immunic Australia Pty. Ltd. M